Try our Advanced Search for more refined results
Life Sciences
- 
									September 24, 2025
									Minn. Justices Reject Humana's Pharmacy Sourcing AppealThe Minnesota Supreme Court rejected arguments by a Humana subsidiary that its sales of pharmacy benefit services attributed to Minnesota should instead be sourced to a Humana unit in Wisconsin, denying the company a $834,000 refund Wednesday. 
- 
									September 24, 2025
									9th Circ. Allows One More Go-Round In Kleenex Ad FightThe Ninth Circuit Wednesday determined it does not have jurisdictional authority to revive a proposed class action alleging Kimberly-Clark Corp.'s Kleenex Germ Removal Wet Wipes mislead consumers about the product's ability to kill germs, saying the consumers were not able to establish subject matter jurisdiction. 
- 
									September 24, 2025
									ITC's IP Cases Mainly Target Computer And Telecom ProductsNew data from the U.S. International Trade Commission has shown that intellectual property activity at the agency in 2024 remained relatively the same, with investigations primarily looking into computer and telecommunications products. 
- 
									September 24, 2025
									Blank Rome Hires Bicoastal Pair Of Patent AttysBlank Rome LLP announced Tuesday that it has welcomed two new patent attorneys to its ranks: a Los Angeles-based firm alum and a New York-based former Leason Ellis LLP lawyer. 
- 
									September 24, 2025
									Labcorp, Natera Resolve DNA Sequencing IP Suits MidtrialLabcorp and Natera have reached a midtrial settlement over the laboratory testing giant's claims that its competitor infringed a group of DNA sequencing patents through the sale of a cancer testing product, a Delaware federal judge said. 
- 
									September 24, 2025
									PE-Focused Debt Finance Pro Boosts Cooley's Boston OfficeCooley LLP has grown its debt finance practice in Boston with the addition of a Choate Hall & Stewart LLP attorney. 
- 
									September 23, 2025
									UC Researchers Win Expanded Injunction Against Grant CutsA California federal judge Monday issued another preliminary injunction ordering the Trump administration to reinstate grants awarded to University of California researchers, this time resurrecting grants awarded by the U.S. Department of Defense, the U.S. Department of Transportation and the National Institutes of Health. 
- 
									September 23, 2025
									OTC Drug Co. Must Face Shampoo Cancer Risk Class ActionA Pennsylvania federal judge denied Lake Consumer Products Inc.'s request to toss a putative class action alleging it manufactures coal tar shampoo with known carcinogens, reasoning that most of the claims against the company were plausible enough to move forward. 
- 
									September 23, 2025
									CBP Says It Didn't Coordinate With Apple In Import Ban CaseU.S. Customs and Border Protection told a D.C. federal court Monday that contrary to claims by Masimo Corp., emails between the agency and Apple Inc. do not show the two worked together to evade an import ban on the Apple Watch in a patent dispute with Masimo. 
- 
									September 23, 2025
									Eli Lilly Deal In Weight Loss Drugs Trademark Suit Hits SnagPharmaceutical giant Eli Lilly and two Seattle-area medical clinics tried to leave a federal court "entirely in the dark" on the finer points of their newly proposed trademark suit settlement, a Seattle federal judge held in declining to approve the deal and enter a consent judgment in the case. 
- 
									September 23, 2025
									Google, Meta Beat BlueChew Users' Privacy Suit, For NowA California federal judge Tuesday dismissed a proposed class action alleging Google and Meta illegally gathered information from website users buying erectile dysfunction medication on BlueChew's website, since BlueChew's revised policy makes clear their personal data consisting of health information would be shared with third parties for advertising purposes. 
- 
									September 23, 2025
									Stem Cell Co. Beats Investor Suit Over Failed Janssen CollabBiopharmaceutical company Fate Therapeutics Inc. has shed a proposed investor class action alleging it concealed manufacturing challenges, precipitating the blowup of a potentially lucrative partnership, after a San Diego federal judge found its investors failed to show how their losses were caused by the company's alleged misstatements. 
- 
									September 23, 2025
									This Week In Healthcare CybersecurityExpiring Obama-era cybersecurity legislation, U.K. charges for 'Scattered Spider' breach, and the challenges of 23andMe's bankruptcy. Law360 looks at the week in cybersecurity developments affecting the healthcare industry. 
- 
									September 23, 2025
									Axsome Settles Investors' Drug Approval Suit For $7.8MBiopharmaceutical company Axsome Therapeutics Inc. and its shareholders have asked a New York federal court to approve a $7.75 million settlement to resolve investors' claims that Axsome hid issues related to gaining regulatory approval for its migraine drug. 
- 
									September 23, 2025
									Fed. Circ. Gives Bayer Chance To Save Xarelto Patent ClaimsThe Federal Circuit revived several claims of a patent underpinning Bayer Pharma Aktiengesellschaft's blockbuster blood thinner Xarelto on Tuesday, sending the challenge brought by Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc. and a Cipla unit back to the Patent Trial and Appeal Board. 
- 
									September 23, 2025
									Tylenol MDL In Spotlight After Trump Blasts Use In PregnancyThe Trump administration's attack on the use of acetaminophen during pregnancy drew on the work of a Harvard expert whose analysis is central to a legal clash now before a federal appeals court. The president's broadside promises to energize plaintiffs. 
- 
									September 23, 2025
									How Attys Are Riding The Mass. Biotech 'Roller Coaster'The first half of 2025 saw the Massachusetts biotech industry post bleak numbers, including a dip in venture capital funding and merger activity, leaving attorneys looking for creative ways to help companies with fewer public and private dollars. 
- 
									September 23, 2025
									NC Sens. Vote To Cut Planned Parenthood's Medicaid FundsRepublican state senators in North Carolina have greenlit a bill that would revoke Medicaid funding for Planned Parenthood, aligning the Tar Heel state with the president's "One Big Beautiful Bill," which prohibits Medicaid funding for nonprofit groups that provide abortion services. 
- 
									September 23, 2025
									Pfizer Settles Conn. Zantac Lawsuits Alleging Cancer RisksPfizer Inc. has settled two Connecticut state court lawsuits by patients who claimed generic forms of ranitidine, the heartburn and acid reflux drug sold under the brand name Zantac, degraded into a substance that caused cancer. 
- 
									September 23, 2025
									EX-CTA Worker's $425K Vaccine Bias Award Capped At $300KAn Illinois federal judge lowered a former Chicago Transit Authority employee's $425,000 jury award to $300,000 Tuesday for the ex-worker's claim that he was wrongly fired for refusing the COVID-19 vaccine, entering a judgment the judge said he'll later amend with awards that include back and front pay. 
- 
									September 23, 2025
									Two Longtime HHS Attys Depart Posts For Crowell & MoringTwo prominent U.S. Department of Health and Human Services attorneys have left their posts for Crowell & Moring LLP after more than two decades in the federal government. 
- 
									September 23, 2025
									Foley & Lardner Adds Healthcare Deals Pro From Holland & KnightFoley & Lardner LLP has continued its expansion in Nashville with the addition of another former Holland & Knight LLP attorney, expanding its healthcare and life sciences and manufacturing sector capabilities. 
- 
									September 23, 2025
									HealthTrackRx Names 2nd Chief Legal Officer In 2025Texas-based infectious disease laboratory HealthTrackRx has added a new chief legal officer following the departure of the top attorney it hired earlier this year. 
- 
									September 22, 2025
									5th Circ.'s 340B Ruling 'Limited,' Pharma Cos. Tell 4th Circ.The Fifth Circuit's recent refusal to block a Mississippi law regulating the delivery of discounted drugs to rural providers can't be wielded by West Virginia in its battle over the law's constitutionality because of the distinctions between the two state laws, a coalition of pharmaceutical companies told the Fourth Circuit. 
- 
									September 22, 2025
									In-House Judge Won't Pause FTC's Heart Valve Deal ChallengeAn administrative law judge refused to pause the Federal Trade Commission's in-house case challenging Edwards Lifesciences Corp.'s planned $945 million purchase of JenaValve Technology Inc. until after a ruling in the related federal court case. 
Expert Analysis
- 
								
								How McKesson Ruling Will Inform Interpretations Of The TCPA  Amid the U.S. Supreme Court's ruling in McLaughlin Chiropractic Associates v. McKesson, we can expect to see both plaintiffs and defendants utilizing the decision to revisit the Federal Communications Commission's past Telephone Consumer Protection Act interpretations and decisions they did not like, says Jason McElroy at Saul Ewing. 
- 
								
								AbbVie Frees Taxpayers From M&A Capital Loss Limitations.jpg)  The U.S. Tax Court’s June 17 opinion in AbbVie v. Commissioner, finding that a $1.6 billion break fee was an ordinary and necessary business expense, marks a pivotal rejection of the Internal Revenue Service’s position on the tax treatment of termination fees related to failed mergers or acquisitions, say attorneys at Holland & Knight. 
- 
								Opinion New USPTO Leadership Must Address Low-Quality Patents  With John Squires in line to become the new director of the U.S. Patent and Trademark Office, the agency has an opportunity to refocus its mission on prioritizing quality in patent examination and taking a harsher stance against low-quality patents and patent trolls, says Jill Crosby at Engine Advocacy & Foundation. 
- 
								Opinion High Court Must Overrule Outdated Patent Eligibility Doctrine_page-0001.jpg)  A certiorari petition should directly ask the U.S. Supreme Court to correct its 1972 patent decision in Gottschalk v. Benson, the critical point where patent eligibility law veered from the statutory text toward judicial policymaking, says Robert Greenspoon at Dunlap Bennett. 
- 
								Series Playing The Violin Makes Me A Better Lawyer  Playing violin in a string quartet reminds me that flexibility, ambition, strong listening skills, thoughtful leadership and intentional collaboration are all keys to a successful legal practice, says Julie Park at MoFo. 
- 
								
								The State Of AI Adoption In The Patent Field  The use of generative artificial intelligence in patent-related practices has lagged behind early predictions, which may be explained by a number of core concerns that organizations must address before seriously considering adoption, say attorney Michael Drapkin and leadership coach Michael Colacchio. 
- 
								
								Purdue Case Could Transform Patent Obviousness Analyses  If accepted for review by the U.S. Supreme Court, Purdue Pharma v. Accord Healthcare — concerning whether Purdue's abuse-deterrent opioid formulation patents were invalid as obvious — could significantly shift how courts weigh secondary considerations in patent obviousness analyses, say attorneys at Lathrop. 
- 
								
								Federal Regs Order May Spell Harsher FDCA Enforcement  A recent executive order aimed at reducing criminal prosecutions of those who unknowingly violate complex federal regulations may actually lead to more aggressive felony indictments under the Federal Food, Drug and Cosmetic Act, but companies and executives can mitigate risks by following several key principals, say attorneys at McGuireWoods. 
- 
								Series Law School's Missed Lessons: Practicing Self-Care  Law schools don’t teach the mental, physical and emotional health maintenance tools necessary to deal with the profession's many demands, but practicing self-care is an important key to success that can help to improve focus, manage stress and reduce burnout, says Rachel Leonard at MG+M. 
- 
								
								ABA Opinion Makes It A Bit Easier To Drop A 'Hot Potato'  The American Bar Association's recent ethics opinion clarifies when attorneys may terminate clients without good cause, though courts may still disqualify a lawyer who drops a client like a hot potato, so sending a closeout letter is always a best practice, say attorneys at Thompson Hine. 
- 
								
								IRhythm IPR Denial Raises Key PTAB Discretion Questions  By giving the passage of time a dispositive role in denying institution of five inter partes review petitions filed by iRhythm Technologies, the U.S. Patent and Trademark Office has upended the strategic considerations for filing and defending against IPRs, disclosing prior art during prosecution, and engaging in licensing negotiations, say attorneys at Dentons. 
- 
								
								Canadian Suit Offers Disclosure Lesson For US Cannabis Cos.  A Canadian class action asserting that Aurora Cannabis failed to warn consumers about the risk of developing cannabinoid hyperemesis syndrome may spawn copycat filings in the U.S., and is a cautionary tale for cannabis and hemp industries to prioritize risk disclosure, says Ian Stewart at Wilson Elser. 
- 
								Opinion IPR Denial In IRhythm Should Not Set A Blanket Rule  Though the Patent Trial and Appeal Board's discretionary denial in iRhythm v. Welch Allyn last month raised concerns that mere knowledge of a patent could bar inter partes review institution, a closer look at the facts and reasoning reveals why this case's holdings should not be reflexively applied to all petitioners, says David McCombs at Haynes Boone. 
- 
								
								What High Court's Tenn. Trans Care Ruling Means Nationally  The U.S. Supreme Court's decision in U.S. v. Skrmetti, upholding a Tennessee ban on gender-affirming medical care for minors, is fairly limited in scope and closely tailored to the specific language of Tennessee's law, but it may have implications for challenges to similar laws in other states, say attorneys at Hall Render. 
- 
								
								How Trump's Trade Policies Are Shaping Foreign Investment.jpg)  Five months into the Trump administration, investors are beginning to see the concrete effects of the president’s America First Investment Policy as it presents new opportunities for clearing transactions more quickly, while sustaining risk aversion related to Chinese trade and potentially creating different political risks, say attorneys at Covington.